'Rapid' path for Curis' lead leukemia drug hits road­block with par­tial clin­i­cal hold af­ter pa­tient death

A pa­tient has died in a Phase I/IIa tri­al of Curis’ lead drug af­ter ex­pe­ri­enc­ing rhab­domy­ol­y­sis, “among sev­er­al con­di­tions.” As a re­sult, FDA has slapped …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER